Despite research showing that adverse reactions to the epilepsy drug Carbamazepine are highly frequent, patients who have such reactions will not qualify for the Department of Health’s (DOH) drug relief program because the drug is mainly prescribed by doctors for “off-label” use, Democratic Progressive Party (DPP) Legislator Huang Sue-ying (黃淑英) said yesterday.
At a press conference yesterday, Huang cited the case of a man, surnamed Hsu (徐), who had experienced an adverse reaction to the drug but could not receive drug relief compensation, saying that this highlighted a serious problem caused by the failure of the health authorities to provide the public with protection against drugs that were prescribed off-label.
Doctors may legally prescribe drugs off-label if the drug is safe to use and found to be effective in treating a certain condition that it has not yet been approved for. For example, Carbamazepine, which has been officially approved for use in treating epilepsy, is also often prescribed by doctors as a mood stabilizer or pain reliever.
“While it is legal for doctors to prescribe drugs off-label, patients who follow their doctor’s instructions to take the drug cannot receive any help or compensation if they have an adverse reaction because the DOH’s drug relief program then deems off-label use illegal, which is unreasonable,” Huang said.
Huang cited statistics from the Drug Relief Foundation, which showed that from 2005 until last year, there were 299 cases of patients who had adverse reactions to drugs but could not receive compensation. Of the 299 cases, 101 (34 percent) were patients who used off-label drugs.
She also cited a research study by Academia Sinica in April 2004 that showed as many as 5 percent of people in Taiwan carry a gene that has shown to increase the risk of developing Stevens Johnson syndrome as a reaction to taking Carbamazepine. As a result, compared with the relatively low rate of white Caucasians who carry this gene, Taiwanese are 30 times more at risk of developing the syndrome in reaction to the drug.
Huang urged DOH officials to re-evaluate whether Carbamazepine should be legally approved as safe for use in the country, as well as provide drug relief for patients who suffer from adverse drug reactions as a result of off-label use.
Hsu Chien-wen (喋??, deputy director of the Food and Drug Administration’s division of drug and new biotechnology products, said that as no drug is 100 percent safe, doctors are advised to continue monitoring patients’ progress while they are taking them.
She said DOH officials would invite experts to discuss drug relief assistance and compensation.
Alain Robert, known as the "French Spider-Man," praised Alex Honnold as exceptionally well-prepared after the US climber completed a free solo ascent of Taipei 101 yesterday. Robert said Honnold's ascent of the 508m-tall skyscraper in just more than one-and-a-half hours without using safety ropes or equipment was a remarkable achievement. "This is my life," he said in an interview conducted in French, adding that he liked the feeling of being "on the edge of danger." The 63-year-old Frenchman climbed Taipei 101 using ropes in December 2004, taking about four hours to reach the top. On a one-to-10 scale of difficulty, Robert said Taipei 101
Nipah virus infection is to be officially listed as a category 5 notifiable infectious disease in Taiwan in March, while clinical treatment guidelines are being formulated, the Centers for Disease Control (CDC) said yesterday. With Nipah infections being reported in other countries and considering its relatively high fatality rate, the centers on Jan. 16 announced that it would be listed as a notifiable infectious disease to bolster the nation’s systematic early warning system and increase public awareness, the CDC said. Bangladesh reported four fatal cases last year in separate districts, with three linked to raw date palm sap consumption, CDC Epidemic Intelligence
US climber Alex Honnold left Taiwan this morning a day after completing a free-solo ascent of Taipei 101, a feat that drew cheers from onlookers and gained widespread international attention. Honnold yesterday scaled the 101-story skyscraper without a rope or safety harness. The climb — the highest urban free-solo ascent ever attempted — took just more than 90 minutes and was streamed live on Netflix. It was covered by major international news outlets including CNN, the New York Times, the Guardian and the Wall Street Journal. As Honnold prepared to leave Taiwan today, he attracted a crowd when he and his wife, Sanni,
Taiwanese and US defense groups are collaborating to introduce deployable, semi-autonomous manufacturing systems for drones and components in a boost to the nation’s supply chain resilience. Taiwan’s G-Tech Optroelectronics Corp subsidiary GTOC and the US’ Aerkomm Inc on Friday announced an agreement with fellow US-based Firestorm Lab to adopt the latter’s xCell, a technology featuring 3D printers fitted in 6.1m container units. The systems enable aerial platforms and parts to be produced in high volumes from dispersed nodes capable of rapid redeployment, to minimize the risk of enemy strikes and to meet field requirements, they said. Firestorm chief technology officer Ian Muceus said
RSS